British Society for Rheumatology

RHEUMATOLOGY

OXFORD

Correction

Correction: Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus

This is a correction to: Simone Cosima Boedecker-Lips and others, Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus, *Rheumatology*, Volume 62, Issue 3, March 2023, Pages e34–e35, https://doi.org/10.1093/rheumatology/keac459

In the originally published version of this manuscript, in Table 1, the first line under "vaccine type" should begin "AstraZeneca" instead of the value "10(11%)". The value "10(11%) should be placed under column "BEL, *n*=88". The value from the "overall" column was also missing ("12 (8.2%"). Table 1 should read:

Table 1. SARS-CoV-2 vaccines, number of vaccinations, intervals between vaccinations, and anti-SARS-CoV-2 antibody levels

Vaccination	Overall, *n* = 147	BEL, *n* = 88	no BEL, *n* = 59	*P*-value
Vaccine type				0.2
AstraZeneca	12 (8.2%)	10 (11%)	2 (3.4%)	
Biontech	116 (79%)	66 (75%)	50 (85%)	
Moderna	19 (13%)	12 (14%)	7 (12%)	
No. of vaccinations				>0.9
2	5 (10%)	3 (10%)	2 (10%)	
3	43 (86%)	26 (87%)	17 (85%)	
Days between 1st and 2nd shot	42 (33, 56)	41 (36, 50)	42 (31, 61)	0.7
Anti-SARS-CoV-2 IgG after second shot (AU/ml)	812 (130, 5358)	265 (91, 5410)	3382 (1152, 5061)	0.078
Days between 2nd and 3rd shot	194 (168, 215)	196 (182, 220)	186 (158, 214)	0.4
Anti-SARS-CoV-2 IgG after third shot (AU/ml)	3405 (1386, 11 032)	2657 (906, 5382)	6258 (3010, 12 858)	0.12

Days and antibody levels are given as medians with interquartile ranges. Statistical significance between the BEL and no-BEL groups was assessed by Wilcoxon rank sum exact test.

instead of:

Table 1. SARS-CoV-2 vaccines, number of vaccinations, intervals between vaccinations, and anti-SARS-CoV-2 antibody levelsAstraZeneca12 (8.2%)

Vaccination	Overall, *n* = 147	BEL, *n* = 88	no BEL, *n* = 59	*P*-value
Vaccine type				0.2
10 (11%)	2 (3.4%)			
Biontech	116 (79%)	66 (75%)	50 (85%)	
Moderna	19 (13%)	12 (14%)	7 (12%)	
No. of vaccinations				>0.9
2	5 (10%)	3 (10%)	2 (10%)	
3	43 (86%)	26 (87%)	17 (85%)	
Days between 1st and 2nd shot	42 (33, 56)	41 (36, 50)	42 (31, 61)	0.7
Anti-SARS-CoV-2 IgG after second shot (AU/ml)	812 (130, 5358)	265 (91, 5410)	3382 (1152, 5061)	0.078
Days between 2nd and 3rd shot	194 (168, 215)	196 (182, 220)	186 (158, 214)	0.4
Anti-SARS-CoV-2 IgG after third shot (AU/ml)	3405 (1386, 11 032)	2657 (906, 5382)	6258 (3010, 12 858)	0.12

Days and antibody levels are given as medians with interquartile ranges. Statistical significance between the BEL and no-BEL groups was assessed by Wilcoxon rank sum exact test.

These errors have been corrected in the article.